Evidence map›Paper›PMID 30963446›Full record

ArticleInternational journal of clinical pharmacy2019

Usability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventions.

Fernanda S Tonin, Livia A Lopes, Inajara Rotta, Aline F Bonetti, Roberto Pontarolo, Cassyano J Correr, Fernando Fernandez-Llimos

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fernanda S ToninPharmaceutical Sciences Postgraduate Programme, Federal University of Paraná, Curitiba, Brazil.ORCID http://orcid.org/0000-0003-4262-8608
Livia A LopesPharmaceutical Sciences Postgraduate Programme, Federal University of Paraná, Curitiba, Brazil.
Inajara RottaHospital de Clínicas, Federal University of Paraná, Curitiba, Brazil.
Aline F BonettiPharmaceutical Sciences Postgraduate Programme, Federal University of Paraná, Curitiba, Brazil.
Roberto PontaroloDepartment of Pharmacy, Federal University of Paraná, Curitiba, Brazil.ORCID http://orcid.org/0000-0002-7049-4363
Cassyano J CorrerDepartment of Pharmacy, Federal University of Paraná, Curitiba, Brazil.ORCID http://orcid.org/0000-0002-4676-5266
Fernando Fernandez-LlimosResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal. f-llimos@ff.ul.pt.ORCID http://orcid.org/0000-0002-8529-9595

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The Cochrane collaboration risk of bias assessment (RoB) tool is used in several fields to evaluate the methodological quality of studies. Its strengths and challenges are discussed. Objective To assess the sensitivity of the RoB tool in studies of pharmacist interventions. Setting DEPICT database was used to pool randomized controlled trials (RCTs) of complex interventions. Method A Guide for RoB Judgment in Pharmacy Services was created to help in the interpretation and judgment of bias criteria. The evaluation of bias (low, unclear, high risk) was performed by RCT. Sensitivity analyses were performed to assess the influence of different interpretations of eight elements of judgment in the RoB tool. Paired analysis and estimations of the effect size (95% confidence interval) of the criteria modifications compared to the original analyses were calculated. Main outcome measure Changes in the interpretations of judgment in the RoB tool. Results Overall, 8.3, 45.4, and 46.3% of the studies were determined to have low, unclear, and high risk of bias, respectively. High risk of bias was caused by attrition and detection domains. The number of studies classified with high risk of bias significantly increased for five of the eight interpretations, while unclear risk of bias increased for three interpretations (with a negligible effect size in all of them). Lack of blinding, loss of participants, and the use of subjective and self-reported outcomes were the main elements resulting in high risk of bias. Conclusion The RoB tool is useful for evaluating RCTs of pharmacist interventions if adapted criteria for judgment are used. Ignoring these adjustments produces a floor-effect with studies classified with high risk of bias.

Indexed as

Professional RoleBiasDatabases, FactualHumansPharmacistsRandomized Controlled Trials as TopicReproducibility of ResultsRisk AssessmentCochrane collaborationMethodologyOutcome assessmentPharmacistsRisk of biasRoB tool

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.